# US 2015/0175704 A1 · Anti-nr10 antibody and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0175704 A1
- Document ID: US20150175704A1
- Status: Published application
- Kind: A1
- Application number: 14/340,883
- Filed: 2014-07-25
- Published: 2015-06-25
- Earliest claimed: 2007-12-05
- Assignees: Chugai Seiyaku Kabushiki Kaisha
- Applicants: Chugai Seiyaku Kabushiki Kaisha
- Inventors: Taichi Kuramochi; Keiko Kasutani; Souhei Ohyama; Hiroyuki Tsunoda; Tomoyuki Igawa; Tatsuhiko Tachibana; Hirotake Shiraiwa; Keiko Esaki
- Web page: https://patentgrep.com/patent/US20150175704A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- G01N 33/6869: {Interleukin}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2333/7155: for interleukins [IL]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present inventors successfully obtained anti-NR10 antibodies having an effective neutralizing activity against NR10. The anti-NR10 antibodies provided by the present invention are useful as, for example, pharmaceuticals for treating or preventing inflammatory diseases.

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

A purified anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs: 1-3, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs: 5-7, respectively.

### Claim 15

A purified anti-NR10 antibody comprising a heavy chain variable region comprising SEQ ID NO: 4.

### Claim 16 (depends on 15)

The purified antibody of claim 15, further comprising a light chain variable region comprising SEQ ID NO: 8.

### Claim 17

A purified anti-NR10 antibody that binds to the same epitope bound by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 4 and a light chain variable region comprising SEQ ID NO: 8.

### Claim 18

A purified anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs: 9-11, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs: 13-15, respectively.

### Claim 19

A purified anti-NR10 antibody comprising a heavy chain variable region comprising SEQ ID NO: 12.

### Claim 20 (depends on 19)

The purified antibody of claim 19, further comprising a light chain variable region comprising SEQ ID NO: 16.

### Claim 21

A purified anti-NR10 antibody that binds to the same epitope bound by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 12 and a light chain variable region comprising SEQ ID NO: 16.

### Claim 22

A purified anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs: 17-19, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs: 21-23, respectively.

### Claim 23

A purified anti-NR10 antibody comprising a heavy chain variable region comprising SEQ ID NO: 20.

### Claim 24 (depends on 23)

The purified antibody of claim 23, further comprising a light chain variable region comprising SEQ ID NO: 24.

### Claim 25

A purified anti-NR10 antibody that binds to the same epitope bound by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 20 and a light chain variable region comprising SEQ ID NO: 24.

### Claim 26

A purified anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs: 25-27, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs: 29-31, respectively.

### Claim 27

A purified anti-NR10 antibody comprising a heavy chain variable region comprising SEQ ID NO: 28.

### Claim 28 (depends on 27)

The purified antibody of claim 27, further comprising a light chain variable region comprising SEQ ID NO: 32.

### Claim 29

A purified anti-NR10 antibody that binds to the same epitope bound by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 28 and a light chain variable region comprising SEQ ID NO: 32.

### Claim 30 (depends on 14)

A pharmaceutical composition comprising the antibody of claim 14.

### Claim 31 (depends on 18)

A pharmaceutical composition comprising the antibody of claim 18.

### Claim 32 (depends on 22)

A pharmaceutical composition comprising the antibody of claim 22.

### Claim 33 (depends on 26)

A pharmaceutical composition comprising the antibody of claim 26.

### Claim 34 (depends on 30)

The pharmaceutical composition of claim 30, further comprising a pharmaceutically acceptable carrier.

### Claim 35 (depends on 30)

The pharmaceutical composition of claim 30, comprising an ingredient selected from the group consisting of a surfactant, an excipient, an antioxidant, a coloring agent, a flavoring agent, a preservative, a stabilizer, a buffering agent, a chelating agent, a suspending agent, an isotonizing agent, a binder, a disintegrator, a lubricant, a fluidity promoter, and a corrigent.

### Claim 36 (depends on 30)

The pharmaceutical composition of claim 30, comprising an ingredient selected from the group consisting of light anhydrous silicic acid, lactose, crystalline cellulose, mannitol, starch, carmelose calcium, carmelose sodium, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylacetaldiethylaminoacetate, polyvinylpyrrolidone, gelatin, medium chain fatty acid triglyceride, polyoxyethylene hydrogenated castor oil 60, sucrose, carboxymethylcellulose, corn starch, and inorganic salt.

### Claim 37 (depends on 30)

The pharmaceutical composition of claim 30, comprising at least one low-molecular-weight polypeptide.

### Claim 38 (depends on 30)

The pharmaceutical composition of claim 30, comprising serum albumin or gelatin or both.

### Claim 39 (depends on 30)

The pharmaceutical composition of claim 30, further comprising at least one amino acid.

### Claim 40 (depends on 39)

The pharmaceutical composition of claim 39, wherein the at least one amino acid is selected from the group consisting of glycine, glutamine, asparagine, arginine, and lysine.

### Claim 41 (depends on 30)

The pharmaceutical composition of claim 30, wherein the composition is an isotonic aqueous solution suitable for injection.

### Claim 42 (depends on 41)

The pharmaceutical composition of claim 41, wherein the aqueous solution comprises physiological saline or dextrose or both.

### Claim 43 (depends on 41)

The pharmaceutical composition of claim 41, comprising an ingredient selected from the group consisting of D-sorbitol, D-mannose, D-mannitol, and sodium chloride.

### Claim 44 (depends on 30)

The pharmaceutical composition of claim 30, comprising a solubilizing agent.

### Claim 45 (depends on 44)

The pharmaceutical composition of claim 44, wherein the solubilizing agent is an alcohol, a polyalcohol, or a non-ionic detergent.

### Claim 46 (depends on 30)

The pharmaceutical composition of claim 30, comprising a microcapsule in which the antibody is encapsulated.

### Claim 47 (depends on 46)

The pharmaceutical composition of claim 46, wherein the microcapsule comprises hydroxymethylcellulose, gelatin, or polymethylmethacrylate.

### Claim 48 (depends on 30)

The pharmaceutical composition of claim 30, wherein the composition is a colloidal drug delivery system.

### Claim 49 (depends on 48)

The pharmaceutical composition of claim 48, wherein the colloidal drug delivery system is selected from the group consisting of liposomes, albumin microspheres, a microemulsion, nano-particles, and nano-capsules.

### Claim 50 (depends on 30)

The pharmaceutical composition of claim 30, wherein the composition is a sustained-release formulation.

### Claim 51

Nucleic acid of any one of (a) to (d) below:
(a) nucleic acid encoding an antibody that recognizes domain 1 of NR10;
(b) an isolated nucleic acid encoding a protein comprising the amino acid sequence of any one of SEQ ID NOs: 1-32;
(c) an isolated nucleic acid encoding a protein that (i) comprises the amino acid sequence of any one of SEQ ID NOs: 1-32 in which one or more amino acids are replaced, deleted, inserted and/or added and (ii) binds to the same epitope as is bound by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 4 and a light chain variable region comprising SEQ ID NO: 8, or by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 12 and a light chain variable region comprising SEQ ID NO: 16, or by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 20 and a light chain variable region comprising SEQ ID NO: 24, or by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 28 and a light chain variable region comprising SEQ ID NO: 32; and
(d) an isolated nucleic acid that (i) hybridizes under stringent conditions with the nucleotide sequence of any one of SEQ ID NOs: 1-32, and (ii) encodes a polypeptide that binds to the same epitope as is bound an antibody comprising a heavy chain variable region comprising SEQ ID NO: 4 and a light chain variable region comprising SEQ ID NO: 8, or by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 12 and a light chain variable region comprising SEQ ID NO: 16, or by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 20 and a light chain variable region comprising SEQ ID NO: 24, or by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 28 and a light chain variable region comprising SEQ ID NO: 32.

### Claim 52 (depends on 51)

A vector or vectors comprising the nucleic acid of claim 51.

### Claim 53 (depends on 52)

A host cell containing the vector or vectors of claim 52.

### Claim 54 (depends on 53)

A method for producing a protein or an antibody, the method comprising culturing the host cell of claim 53 so that the protein or antibody encoded on the vector or vectors is expressed.

### Claim 55

A method for producing an anti-NR10 antibody, the method comprising providing a cell containing recombinant nucleic acid encoding an antibody that recognizes domain 1 of NR10 and culturing the cell in vitro so that the antibody is expressed by the cell.

### Claim 56

A composition comprising an antibody that recognizes domain 1 of NR10, the antibody being covalently linked to a molecule selected from the group consisting of a polymeric substance, hyaluronic acid, a radioactive substance, a fluorescent substance, a luminescent substance, an enzyme, and a toxin.

### Claim 57 (depends on 56)

A method for obtaining the composition of claim 56, the method comprising chemically conjugating the molecule to an antibody that recognizes domain 1 of NR10.

### Claim 58

A method for measuring the activity of an anti-NR10 antibody, the method comprising contacting the antibody with cells of an interleukin 31 (IL-31)-dependent cell line and determining whether the antibody suppresses growth of the cells.

### Claim 59

A method for determining the NR10-binding activity of an anti-NR10 antibody, the method comprising use of a technique selected from ELISA (enzyme-linked immunosorbent assay), EIA (enzyme immunoassay), RIA (radioimmunoassay) and fluorescent antibody assay to determine the NR10-binding activity of the anti-NR10 antibody.

### Claim 60 (depends on 59)

The method of claim 59, wherein the method comprises use of an enzyme immunoassay that comprises:
(a) contacting a sample containing an anti-NR10 antibody with an NR10-coated plate;
(b) adding to the plate a secondary antibody that is labeled with an enzyme, wherein the secondary antibody binds to the anti-NR10 antibody;
(c) incubating the plate with the antibodies;
(d) washing the plate;
(e) adding a substrate for the enzyme to the plate; and
(f) measuring absorbance to detect enzymatic alteration of the substrate, as a measure of the NR10-binding activity of the anti-NR10 antibody.

### Claim 61

A method for treating or preventing an inflammatory disease in a subject in recognized need thereof, the method comprising administering to the subject an antibody that recognizes domain 1 of NR10.

### Claim 62 (depends on 61)

The method of claim 61, wherein the inflammatory disease is a disease with pathological features involved in cytological and histological reactions that occur in affected blood vessels and adjacent tissues in response to an injury or abnormal stimulation caused by a physical, chemical, or biological agent.

### Claim 63

A method for isolating and purifying an antibody that recognizes domain 1 of NR10, the method comprising subjecting a sample comprising the antibody to a method comprising a combination of multiple techniques selected from column chromatography, filtration, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectrofocusing, dialysis, and recrystallization.

### Claim 64 (depends on 63)

The method of claim 63, wherein the method comprises a column chromatography technique selected from the group consisting of affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse phase chromatography, and adsorption chromatography.

### Claim 65 (depends on 64)

The method of claim 64, wherein the column chromatography technique comprises affinity chromatography using a protein A column or a protein G column.

### Claim 66

An anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs: 196, 197, and 184, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs: 202, 170, and 193, respectively.

### Claim 67

An anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs: 9, 197 and 184, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs: 202, 170, and 193, respectively.

### Claim 68

An anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs: 176, 197, and 184, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs: 202, 170, and 193, respectively.

### Claim 69

An anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs: 9, 198, and 184, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs: 202, 170, and 193, respectively.

### Claim 70

An anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs: 176, 198, and 184, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs: 202, 170, and 193, respectively.

### Claim 71

An anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs: 9, 199, and 184, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs: 203, 170, and 193, respectively.

### Claim 72

An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 206.

### Claim 73 (depends on 72)

The antibody of claim 72, comprising a light chain variable region comprising SEQ ID NO: 220.

### Claim 74

An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 207.

### Claim 75 (depends on 74)

The antibody of claim 74, comprising a light chain variable region comprising SEQ ID NO: 220.

### Claim 76

An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 208.

### Claim 77 (depends on 76)

The antibody of claim 76, comprising a light chain variable region comprising SEQ ID NO: 220.

### Claim 78

An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 209.

### Claim 79 (depends on 78)

The antibody of claim 78, comprising a light chain variable region comprising SEQ ID NO: 220.

### Claim 80

An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 210.

### Claim 81 (depends on 80)

The antibody of claim 80, comprising a light chain variable region comprising SEQ ID NO: 220.

### Claim 82

An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 211.

### Claim 83 (depends on 82)

The antibody of claim 82, comprising a light chain variable region comprising SEQ ID NO: 220.

### Claim 84

An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 212.

### Claim 85 (depends on 84)

The antibody of claim 84, comprising a light chain variable region comprising SEQ ID NO: 220.

### Claim 86

An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 213.

### Claim 87 (depends on 86)

The antibody of claim 86, comprising a light chain variable region comprising SEQ ID NO: 220.

### Claim 88

An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 214.

### Claim 89 (depends on 88)

The antibody of claim 88, comprising a light chain variable region comprising SEQ ID NO: 220.

### Claim 90

An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 215.

### Claim 91 (depends on 90)

The antibody of claim 90, comprising a light chain variable region comprising SEQ ID NO: 220.

### Claim 92

An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 216.

### Claim 93 (depends on 92)

The antibody of claim 92, comprising a light chain variable region comprising SEQ ID NO: 221.

### Claim 94

An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO: 217.

### Claim 95 (depends on 94)

The antibody of claim 94, comprising a light chain variable region comprising SEQ ID NO: 221.

### Claim 96

An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 224.

### Claim 97 (depends on 96)

The antibody of claim 96, comprising a light chain comprising SEQ ID NO: 238.

### Claim 98

An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 225.

### Claim 99 (depends on 98)

The antibody of claim 98, comprising a light chain comprising SEQ ID NO: 238.

### Claim 100

An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 226.

### Claim 101 (depends on 100)

The antibody of claim 100, comprising a light chain comprising SEQ ID NO: 238.

### Claim 102

An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 227.

### Claim 103 (depends on 102)

The antibody of claim 102, comprising a light chain comprising SEQ ID NO: 238.

### Claim 104

An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 228.

### Claim 105 (depends on 104)

The antibody of claim 104, comprising a light chain comprising SEQ ID NO: 238.

### Claim 106

An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 229.

### Claim 107 (depends on 106)

The antibody of claim 106, comprising a light chain comprising SEQ ID NO: 238.

### Claim 108

An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 230.

### Claim 109 (depends on 108)

The antibody of claim 108, comprising a light chain comprising SEQ ID NO: 238.

### Claim 110

An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 231.

### Claim 111 (depends on 110)

The antibody of claim 110, comprising a light chain comprising SEQ ID NO: 238.

### Claim 112

An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 232.

### Claim 113 (depends on 112)

The antibody of claim 112, comprising a light chain comprising SEQ ID NO: 238.

### Claim 114

An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 233.

### Claim 115 (depends on 114)

The antibody of claim 114, comprising a light chain comprising SEQ ID NO: 238.

### Claim 116

An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 234.

### Claim 117 (depends on 116)

The antibody of claim 116, comprising a light chain comprising SEQ ID NO: 239.

### Claim 118

An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO: 235.

### Claim 119 (depends on 118)

The antibody of claim 118, comprising a light chain comprising SEQ ID NO: 239.

### Claim 120

An anti-NR10 antibody that comprises a light chain variable region comprising SEQ ID NO: 220.

### Claim 121

An anti-NR10 antibody that comprises a light chain variable region comprising SEQ ID NO: 221.

### Claim 122

An anti-NR10 antibody that comprises a light chain comprising SEQ ID NO: 238.

### Claim 123

An anti-NR10 antibody that comprises a light chain comprising SEQ ID NO: 239.

### Claim 124

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO: 206 and a light chain variable region comprising SEQ ID NO: 220.

### Claim 125

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO: 207 and a light chain variable region comprising SEQ ID NO: 220.

### Claim 126

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO: 208 and a light chain variable region comprising SEQ ID NO: 220.

### Claim 127

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO: 209 and a light chain variable region comprising SEQ ID NO: 220.

### Claim 128

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO: 210 and a light chain variable region comprising SEQ ID NO: 220.

### Claim 129

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO: 211 and a light chain variable region comprising SEQ ID NO: 220.

### Claim 130

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO: 212 and a light chain variable region comprising SEQ ID NO: 220.

### Claim 131

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO: 213 and a light chain variable region comprising SEQ ID NO: 220.

### Claim 132

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO: 214 and a light chain variable region comprising SEQ ID NO: 220.

### Claim 133

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO: 215 and a light chain variable region comprising SEQ ID NO: 220.

### Claim 134

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 216 and a light chain variable region comprising SEQ ID NO: 221.

### Claim 135

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain variable region comprising SEQ ID NO: 217 and a light chain variable region comprising SEQ ID NO: 221.

### Claim 136

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 224 and a light chain comprising SEQ ID NO: 238.

### Claim 137

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 225 and a light chain comprising SEQ ID NO: 238.

### Claim 138

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 226 and a light chain comprising SEQ ID NO: 238.

### Claim 139

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 227 and a light chain comprising SEQ ID NO: 238.

### Claim 140

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 228 and a light chain comprising SEQ ID NO: 238.

### Claim 141

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 229 and a light chain comprising SEQ ID NO: 238.

### Claim 142

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 230 and a light chain comprising SEQ ID NO: 238.

### Claim 143

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 231 and a light chain comprising SEQ ID NO: 238.

### Claim 144

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 232 and a light chain comprising SEQ ID NO: 238.

### Claim 145

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 233 and a light chain comprising SEQ ID NO: 238.

### Claim 146

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 234 and a light chain comprising SEQ ID NO: 239.

### Claim 147

A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO: 235 and a light chain comprising SEQ ID NO: 239.

### Claim 148

A purified anti-NR10 antibody comprising a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3, and a light chain variable domain comprising a CDR1, a CDR2, and a CDR3, wherein the heavy chain variable domain CDR1 comprises SEQ ID NO: 1.

### Claim 149

A purified anti-NR10 antibody comprising a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3, and a light chain variable domain comprising a CDR1, a CDR2, and a CDR3, wherein the heavy chain variable domain CDR1 comprises SEQ ID NO: 9.

### Claim 150

A purified anti-NR10 antibody comprising a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3, and a light chain variable domain comprising a CDR1, a CDR2, and a CDR3, wherein the heavy chain variable domain CDR1 comprises SEQ ID NO: 17.

### Claim 151

A purified anti-NR10 antibody comprising a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3, and a light chain variable domain comprising a CDR1, a CDR2, and a CDR3, wherein the heavy chain variable domain CDR1 comprises SEQ ID NO: 25.

### Claim 152

A purified anti-NR10 antibody comprising a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3, and a light chain variable domain comprising a CDR1, a CDR2, and a CDR3, wherein the heavy chain variable domain CDR1 comprises SEQ ID NO: 196.

### Claim 153

A purified anti-NR10 antibody comprising a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3, and a light chain variable domain comprising a CDR1, a CDR2, and a CDR3, wherein the heavy chain variable domain CDR1 comprises SEQ ID NO: 176.

### Claim 154

A method of inhibiting the activity of NR10 comprising contacting the NR10 with an antibody that recognizes domain 1 of NR10.

### Claim 155

A method of neutralizing the activity of interleukin 31 in a subject in recognized need thereof, the method comprising introducing into the subject an antibody that recognizes domain 1 of NR10.

### Claim 156

A method for determining the NR10-binding activity of an antibody that recognizes domain 1 of NR10, the method comprising contacting the antibody with a polypeptide comprising domain 1 of NR10 and determining whether the antibody binds to the polypeptide.

### Claim 157

A method for manufacturing an antibody that recognizes domain 1 of NR10, the method comprising making the antibody and assaying whether it binds to a polypeptide comprising domain 1 of NR10.

### Claim 158

A method for manufacturing an antibody that recognizes domain 1 of NR10, the method comprising making the antibody and assaying whether it inhibits a biological activity of interleukin 31.

### Claim 159

A hybridoma producing a glycosylated antibody that recognizes domain 1 of NR10.

### Claim 160

A purified anti-NR10 antibody, wherein the antibody (i) is monoclonal or polyclonal, (ii) is glycosylated, and (iii) binds to the same epitope that is bound by a reference antibody comprising the heavy chain variable region of SEQ ID NO: 12.

### Claim 161 (depends on 160)

The purified antibody of claim 160, wherein the reference antibody comprises the heavy chain variable region of SEQ ID NO: 12 and the light chain variable region of SEQ ID NO: 16.

### Claim 162 (depends on 160)

The purified antibody of claim 160, wherein the purified antibody comprises the heavy chain variable region of SEQ ID NO: 12.

### Claim 163 (depends on 162)

The purified antibody of claim 162, wherein the purified antibody further comprises the light chain variable region of SEQ ID NO: 16.

### Claim 164

A purified anti-NR10 antibody, wherein the antibody (i) is monoclonal or polyclonal, (ii) is glycosylated, and (iii) binds to the same epitope that is bound by a reference antibody comprising a heavy chain variable region that comprises CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs: 9, 10, and 11, and a light chain variable region that comprises CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs: 13, 14, and 15.

### Claim 165 (depends on 164)

The purified antibody of claim 164, wherein the purified antibody comprises:
a heavy chain variable region that comprises CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs: 9, 10, and 11; and
a light chain variable region that comprises CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs: 13, 14, and 15.

### Claim 166

A purified anti-NR10 antibody, wherein the antibody (i) is monoclonal or polyclonal, (ii) is glycosylated, and (iii) binds to the same epitope that is bound by a reference antibody comprising the heavy chain variable region of SEQ ID NO: 28.

### Claim 167 (depends on 166)

The purified antibody of claim 166, wherein the reference antibody comprises the heavy chain variable region of SEQ ID NO: 28 and the light chain variable region of SEQ ID NO: 32.

### Claim 168 (depends on 166)

The purified antibody of claim 166, wherein the purified antibody comprises the heavy chain variable region of SEQ ID NO: 28.

### Claim 169 (depends on 168)

The purified antibody of claim 168, wherein the purified antibody further comprises the light chain variable region of SEQ ID NO: 32.

### Claim 170

A purified anti-NR10 antibody, wherein the antibody (i) is monoclonal or polyclonal, (ii) is glycosylated, and (iii) binds to the same epitope that is bound by a reference antibody comprising a heavy chain variable region that comprises CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs: 25, 26, and 27, and a light chain variable region that comprises CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs: 29, 30, and 31.

### Claim 171 (depends on 170)

The purified antibody of claim 170, wherein the purified antibody comprises:
a heavy chain variable region that comprises CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs: 25, 26, and 27; and
a light chain variable region that comprises CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs: 29, 30, and 31.
